Glucagon-like peptide-1 receptor agonists (GLP1s) are effective antiobesity drugs and the subject of intense debate around insurance coverage due to the large prevalence of obesity and overweight. The estimation of the budget impact associated with GLP1 insurance coverage requires estimates of GLP1 prices that account for manufacturer discounts. The authors applied a peer-reviewed method to estimate the net prices of GLP1s after manufacturer discounts.

中文翻译：

---

新抗肥胖药物的净价格

胰高血糖素样肽 1 受体激动剂 (GLP1) 是有效的抗肥胖药物，并且由于肥胖和超重的普遍存在而成为围绕保险范围的激烈争论的主题。要估计与 GLP1 保险范围相关的预算影响，需要估计考虑了制造商折扣的 GLP1 价格。作者采用同行评审方法来估计制造商折扣后 GLP1 的净价格。